drugset / Trial / NCT07105098

NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

NCT07105098 ↗

Phase 3 Recruiting 284 enrolled Neurocrine Biosciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

Timeline

Start
2025-08-11
Primary completion
2027-11
Completion
2027-11

Drugs

EvaluationDrugModalityDoseRoute
Subject NBI-1117568 Unknown — Oral

Indications